Conclusions The development of incretin-based treatments has helped improve the quality of life and the management of symptoms for patients inflicted with T2DM
UK-licensed GLP-1 agonists include semaglutide (Wegovy, Ozempic), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide, with specific formulations approved for weight management
Neuropediatrics 44:218221 Celestino-Soper PB, Violante S, Crawford EL, Luo R, Lionel AC, Delaby E, Cai G, Sadikovic B, Lee K, Lo C, Gao K, Person RE, Moss TJ, German JR, Huang N, Shinawi M, Treadwell-Deering D, Szatmari P, Roberts W, Fernandez B, Schroer RJ, Stevenson RE, Buxbaum JD, Betancur C, Scherer SW, Sanders SJ, Geschwind DH, Sutcliffe JS, Hurles ME, Wanders RJ, Shaw CA, Leal SM, Cook EH Jr, Goin-Kochel RP, Vaz FM, Beaudet AL (2012) A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism
Refractory SLE patients respond to the proteasome inhibitor bortezomib
Keep that mental scoreboard handy
When prescribed by healthcare professionals and combined with lifestyle changes, they may play a valuable role in restoring sexual health and confidence